Studies have demonstrated that CLL patients with del(13q) as a sole cytogenetic alteration have better clinical outcomes compared to those with +12, del(11q)/ATM, del(17p)/TP53, or even negative CLL FISH results. Here, TP53 is linked to B-cell chronic lymphocytic leukemia.